Dan Lender M.D.
Dan Lender M.D. Associate Professor of Medicine, University of Maryland,
Division of Associate Professor of Medicine, University of Maryland,
Division of Endocrinology, Diabetes and Nutrition
Universidad Nacional Mayor de San Marcos M.D. 1985 Medicine
A. Positions and Honors:
1984 - 1985 MD Degree, Internship; Arzobispo Loayza Hospital Lima, Peru
1985 – 1986 Government's Health Program Lima, Peru
1987 - 1988 Internship, Greater Baltimore Medical Center Baltimore, Maryland
1988 - 1990 Residency in Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Texas
1990 - 1994 Post Graduate Fellowship in Diabetes Mellitus and Endocrinology,
University of Texas Southwestern Medical Center at Dallas
1994 - 1999 Assistant Professor of Internal Medicine, University of Texas Southwestern Medical
Center, Internal Medicine and Endocrinology Attending Staff, Parkland Memorial Hospital
and the Dallas Veterans Affairs Medical Center
1999 - 2000 Clinical Associate Professor at the University of North Carolina in Chapel Hill, Division of Endocrinology
2000 - 2001 Staff physician at The Bortz Diabetes Control Center in Saint Louis, Missouri
2001 - present Associate Professor of Medicine, University of Maryland,
Division of Endocrinology, Diabetes and Nutrition
HONORS AND AWARDS
1998-1999 Teaching award at The University of Texas Southwestern Medical Center in Dallas
9/98 to 7/2001 Recognition for Delivery of Quality Diabetes Care from the American Diabetes Association
2001 Fellow of the American College of Physicians
American Board of Internal Medicine - October 1990 (recertification 2002)
Endocrinology Diabetes & Metabolism - November 1993 (recertification 2002)
Editorial Board, Journal of Diabetes and its Complications
Editorial Board Consultant for the Journal of Clinical Therapeutics.
Reviewer for the Journal of Investigative Medicine
B. Selected peer-reviewed publications:
Mora PF, Ramirez LC, Lender D, Raskin P: Insulin requirements in lipodystrophic diabetes. Diabetic Medicine, 1993; 10: 863-865.
Fuller CJ, Agil A, Lender D, Jialal 1: Superoxide production and LDL oxidation by diabetic
neutrophils. J of Diab and Its Complications 1996, 10:206.
Arauz-Pacheco C, Lender D, Snell PG, Huet B, Ramirez LC, Breen L, Mora P, Raskin P: Relationship between insulin sensitivity, hyperinsulinemia, and insulin-mediated sympathetic activation in normotensive and hypertensive subjects. Amer J of Hypertension 1996, 9(12):1172-78.
Lender D, Arauz-Pacheco C, Adams-Huet B, Raskin P. Essential hypertension is associated with decreased insulin clearance and insulin resistance. Hypertension 1997; 29(l): 111-114.
Lender D, Arauz-Pacheco C, Raskin P, A double-blind comparison of the effects of amiodipine and enalapril on insulin sensitivity in hypertensive patients. Amer J of Hypertension 1999; 12:298-303.
Lender, D#*, Sysco, S. The Metabolic Syndrome and Cardiometabolic Risk: Scope of the Problem and Current Standard of Care. Pharmacotherapy 2006; 26(5 Pt 2): 3S-12S
Haines ST#, Fuke DC, Lender D, Rodgers PT, Sysko SK. Evaluating and
treating cardiometabolic risk factors: a case discussion. Pharmacotherapy
2006; 26(5 Pt 2): 32S-41S.
Rios J, Lender D, Raskin P: Glipizide improves insulin sensitivity independently of its effects on glycemia. Diabetes, 1991; 40(suppl 1):338A.
Lender D, Arauz-Pacheco C, Snell P, et al: Relationship between the degree of insulin resistance and sympathetic activity. Circulation, 1992; 86(supl 1):1-541.
Sullivan K, Arp B, Schnurr-Breen L, Lender D: Evaluation of a product for the detection of microalbuminuria in urine: 24 hour sample vs first morning voids. Diabetes, 1993; 42(suppl 1):192A.
Lender D, Arauz-Pacheco C, Raskin P: Human hypertension is associated with low insulin clearance independently of the degree of insulin sensitivity. Clinical Research Meeting, 1995.
Arauz-Pacheco C, Lender D, Breen L, Mora Mora P, Snell P, Ramirez LC, Raskin P: A double-blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in essential hypertension. Am J Hypertension 1995; 8(4):44A.
Arauz-Pacheco C, Lender D, Breen L, Hartman I, Raskin P: Determinants of insulin sensitivity in women with essential hypertension. American Heart Assoc. Conference on Hormonal, Metabolic and Cellular Influences on Cardiovascular Disease in Women. October, 1995.
Aviles-Santa L, Lender D, Mora P, Huang W, Lan MS, Regis C, Maclaren N, Raskin P. The Relationship Between Immune-Mediated Type 1 Diabetes MeHitus and Ethnicity. Diabetes 1998; 47 (Suppl 1): A235
Piñero-Pilona A, Harris WT, Lender D, Aviles-Santa L: Type 1.5 Diabetes. A Four-Year Follow-up of Cohort from Dallas ("Praire Diabetes"). Diabetes 1999; 48(Suppl 1): Abstract 0352, A 82.
C. Research Support:
Ongoing Research Support
A Novel Paradigm to Bridge the Diabetes Care Disparity Gap: Bringing diabetes education into the primary care setting. (PI)
Invesigator’s initiative. Sponsored by Glaxo Smith Kline.
We hypothesize that bringing diabetes education to the primary care physicians’ offices will greatly improve diabetes management in the primary care setting thus translating to lower rates of diabetes complications, morbidity and mortality, and will help to bridge the diabetes care disparity gap.
Clopidrogel for High Atherthrombotic Risk and Ischemia Stabilization Management and Avoidance (CHARISMA) (PI) Sponsored by: Sanofi-Synthelabo Research
It is a Multinational study. The primary objective is to assess whether clopidogrel 75 mg daily is superior to placebo in preventing the occurrence of major ischemic complications (stroke, MI, cardiovascular death) in high-risk patients aged 45 years or older who are receiving low-dose ASA and other background therapy.
Baltimore Partnership Program to Reduce Cardiovascular Disparities.
The major goal of this project is to build a cardiovascular research disparities program at UMB and an integrated strong research program at a minority serving system.